PPCC 02
Alternative Names: PPCC-02Latest Information Update: 03 Oct 2024
Price :
$50 *
At a glance
- Originator Immorta Bio
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Heart failure
Most Recent Events
- 11 Sep 2024 PPCC 02 is available for licensing as of 11 Sep 2024. https://www.immortabio.com/#collaboration (Immorta Bio pipeline, September 2024)
- 11 Sep 2024 Early research in Heart failure in USA (Parenteral) prior to September2024 (Immorta Bio pipeline, September 2024)
- 30 Nov 2023 Immorta Bio has patent pending for the treatment of heart failure using pluripotent stem cell derived cardiomyocytes in an Unknown location (Immorta Bio website, September 2024)